Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of Antitumor Immune Response Generated After Concurrent Chemo-radiotherapy (cCRT) and IO Treatment in Non-resectable Stage IIIA/B and IIIC NSCLC Patients Treated in Real World.

NCT06634199 is registered in ClinicalTrials.gov with Fundación GECP as lead sponsor.

NCT NCT06634199
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06634199 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of Antitumor Immune Response Generated After Concurrent Chemo-radiotherapy (cCRT) and IO Treatment in Non-resectable Stage IIIA/B and IIIC NSCLC Patients Treated in Real World.
Lead sponsor
Fundación GECP
Phase
Observational
Overall status
Recruiting
Start date
October 3, 2024
Completion date
November 4, 2027
Enrollment
50 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer stage iii, pdl1 gene mutation